Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers
Identifieur interne : 001C32 ( Main/Curation ); précédent : 001C31; suivant : 001C33Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers
Auteurs : I. Fomin [Israël] ; D. Caspi [Israël] ; V. Levy [Israël] ; N. Varsano [Israël] ; Y. Shalev [Israël] ; D. Paran [Israël] ; D. Levartovsky [Israël] ; I. Litinsky [Israël] ; I. Kaufman [Israël] ; I. Wigler [Israël] ; E. Mendelson [Israël] ; O. Elkayam [Israël]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2006-02.
English descriptors
- KwdEn :
- DMARD, disease modifying antirheumatic drug, GMT, geometric mean titre, HA, haemagglutinin, HAQ, Health Assessment Questionnaire, HIT, haemagglutination inhibition test, NA, neuraminidase, RF, rheumatoid factor, TNFα, tumour necrosis factor α, anti-TNFα, influenza, rheumatoid arthritis, vaccination.
- Teeft :
- Arthritis, Arthritis rheum, Blood cells, Disease activity, Dmards, Etanercept, Good humoral response, Haemagglutination, Health assessment questionnaire, Healthy controls, Humoral, Humoral response, Immune response, Immunogenicity, Infliximab, Influenza, Influenza vaccination, Influenza vaccine, Methotrexate, Morning stiffness, Pneumococcal vaccination, Reactive protein, Responder, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatoid patients, Swollen joints, Systemic lupus erythematosus, Tnfa, Tnfa blockers, Tumour necrosis factor, Vaccination, Vaccine, Whole group.
Abstract
Objective: To assess the efficacy and safety of vaccination against influenza virus in patients with rheumatoid arthritis, with special emphasis on the effect of disease modifying antirheumatic drugs (DMARDs), including tumour necrosis factor α (TNFα) blockers. Methods: 82 rheumatoid patients and 30 healthy controls were vaccinated with a split-virion inactivated vaccine containing 15 μg haemagglutinin (HA) per dose of each of B/Hong Kong/330/2001 (HK), A/Panama/2007/99 (PAN), and A/New Caledonian/20/99 (NC). Disease activity was assessed by tender and swollen joint count, morning stiffness, evaluation of pain, Health Assessment Questionnaire, ESR, and C reactive protein on the day of vaccination and six weeks later. Haemagglutination inhibiting (HI) antibodies were tested by a standard WHO procedure. Response was defined as a fourfold or more rise in HI antibodies six weeks after vaccination, or seroconversion in patients with a non-protective baseline level of antibodies (<1/40). Geometric mean titres (GMT) were calculated to assess the immunity of the whole group. Results: Six weeks after vaccination, a significant increase in GMT for each antigen was observed in both groups, this being higher in the healthy group for HK (p = 0.004). The percentage of responders was lower in rheumatoid patients than healthy controls (significant for HK). The percentage of responders was not affected by prednisone or any DMARD, including methotrexate, infliximab, and etanercept. Indices of disease activity remained unchanged. Conclusions: Influenza virus vaccine generated a good humoral response in rheumatoid patients, although lower than in healthy controls. The response was not affected by the use of prednisone or DMARDs.
Url:
DOI: 10.1136/ard.2005.036434
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002359
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :002359
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000B00
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001C44
Links to Exploration step
ISTEX:F1BEADA3E98709F72306672C235D47546767CB17Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers</title>
<author><name sortKey="Fomin, I" sort="Fomin, I" uniqKey="Fomin I" first="I" last="Fomin">I. Fomin</name>
</author>
<author><name sortKey="Caspi, D" sort="Caspi, D" uniqKey="Caspi D" first="D" last="Caspi">D. Caspi</name>
</author>
<author><name sortKey="Levy, V" sort="Levy, V" uniqKey="Levy V" first="V" last="Levy">V. Levy</name>
</author>
<author><name sortKey="Varsano, N" sort="Varsano, N" uniqKey="Varsano N" first="N" last="Varsano">N. Varsano</name>
</author>
<author><name sortKey="Shalev, Y" sort="Shalev, Y" uniqKey="Shalev Y" first="Y" last="Shalev">Y. Shalev</name>
</author>
<author><name sortKey="Paran, D" sort="Paran, D" uniqKey="Paran D" first="D" last="Paran">D. Paran</name>
</author>
<author><name sortKey="Levartovsky, D" sort="Levartovsky, D" uniqKey="Levartovsky D" first="D" last="Levartovsky">D. Levartovsky</name>
</author>
<author><name sortKey="Litinsky, I" sort="Litinsky, I" uniqKey="Litinsky I" first="I" last="Litinsky">I. Litinsky</name>
</author>
<author><name sortKey="Kaufman, I" sort="Kaufman, I" uniqKey="Kaufman I" first="I" last="Kaufman">I. Kaufman</name>
</author>
<author><name sortKey="Wigler, I" sort="Wigler, I" uniqKey="Wigler I" first="I" last="Wigler">I. Wigler</name>
</author>
<author><name sortKey="Mendelson, E" sort="Mendelson, E" uniqKey="Mendelson E" first="E" last="Mendelson">E. Mendelson</name>
</author>
<author><name sortKey="Elkayam, O" sort="Elkayam, O" uniqKey="Elkayam O" first="O" last="Elkayam">O. Elkayam</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F1BEADA3E98709F72306672C235D47546767CB17</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1136/ard.2005.036434</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-CJWVBJG1-0/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002359</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002359</idno>
<idno type="wicri:Area/Istex/Curation">002359</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B00</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B00</idno>
<idno type="wicri:doubleKey">0003-4967:2006:Fomin I:vaccination:against:influenza</idno>
<idno type="wicri:Area/Main/Merge">001C44</idno>
<idno type="wicri:Area/Main/Curation">001C32</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers</title>
<author><name sortKey="Fomin, I" sort="Fomin, I" uniqKey="Fomin I" first="I" last="Fomin">I. Fomin</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Caspi, D" sort="Caspi, D" uniqKey="Caspi D" first="D" last="Caspi">D. Caspi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Levy, V" sort="Levy, V" uniqKey="Levy V" first="V" last="Levy">V. Levy</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Central Virology Laboratory, Public Health Services, Ministry of Health, Sheba Medical Centre, Tel-Hashomer</wicri:regionArea>
<wicri:noRegion>Tel-Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Varsano, N" sort="Varsano, N" uniqKey="Varsano N" first="N" last="Varsano">N. Varsano</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Central Virology Laboratory, Public Health Services, Ministry of Health, Sheba Medical Centre, Tel-Hashomer</wicri:regionArea>
<wicri:noRegion>Tel-Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shalev, Y" sort="Shalev, Y" uniqKey="Shalev Y" first="Y" last="Shalev">Y. Shalev</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Central Virology Laboratory, Public Health Services, Ministry of Health, Sheba Medical Centre, Tel-Hashomer</wicri:regionArea>
<wicri:noRegion>Tel-Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Paran, D" sort="Paran, D" uniqKey="Paran D" first="D" last="Paran">D. Paran</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Levartovsky, D" sort="Levartovsky, D" uniqKey="Levartovsky D" first="D" last="Levartovsky">D. Levartovsky</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Litinsky, I" sort="Litinsky, I" uniqKey="Litinsky I" first="I" last="Litinsky">I. Litinsky</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kaufman, I" sort="Kaufman, I" uniqKey="Kaufman I" first="I" last="Kaufman">I. Kaufman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wigler, I" sort="Wigler, I" uniqKey="Wigler I" first="I" last="Wigler">I. Wigler</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mendelson, E" sort="Mendelson, E" uniqKey="Mendelson E" first="E" last="Mendelson">E. Mendelson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Faculty of Life Sciences, Bar-Ilan University, Ramat Gan</wicri:regionArea>
<wicri:noRegion>Ramat Gan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elkayam, O" sort="Elkayam, O" uniqKey="Elkayam O" first="O" last="Elkayam">O. Elkayam</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2006-02">2006-02</date>
<biblScope unit="volume">65</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="191">191</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DMARD, disease modifying antirheumatic drug</term>
<term>GMT, geometric mean titre</term>
<term>HA, haemagglutinin</term>
<term>HAQ, Health Assessment Questionnaire</term>
<term>HIT, haemagglutination inhibition test</term>
<term>NA, neuraminidase</term>
<term>RF, rheumatoid factor</term>
<term>TNFα, tumour necrosis factor α</term>
<term>anti-TNFα</term>
<term>influenza</term>
<term>rheumatoid arthritis</term>
<term>vaccination</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Blood cells</term>
<term>Disease activity</term>
<term>Dmards</term>
<term>Etanercept</term>
<term>Good humoral response</term>
<term>Haemagglutination</term>
<term>Health assessment questionnaire</term>
<term>Healthy controls</term>
<term>Humoral</term>
<term>Humoral response</term>
<term>Immune response</term>
<term>Immunogenicity</term>
<term>Infliximab</term>
<term>Influenza</term>
<term>Influenza vaccination</term>
<term>Influenza vaccine</term>
<term>Methotrexate</term>
<term>Morning stiffness</term>
<term>Pneumococcal vaccination</term>
<term>Reactive protein</term>
<term>Responder</term>
<term>Rheum</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid arthritis patients</term>
<term>Rheumatoid patients</term>
<term>Swollen joints</term>
<term>Systemic lupus erythematosus</term>
<term>Tnfa</term>
<term>Tnfa blockers</term>
<term>Tumour necrosis factor</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Whole group</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To assess the efficacy and safety of vaccination against influenza virus in patients with rheumatoid arthritis, with special emphasis on the effect of disease modifying antirheumatic drugs (DMARDs), including tumour necrosis factor α (TNFα) blockers. Methods: 82 rheumatoid patients and 30 healthy controls were vaccinated with a split-virion inactivated vaccine containing 15 μg haemagglutinin (HA) per dose of each of B/Hong Kong/330/2001 (HK), A/Panama/2007/99 (PAN), and A/New Caledonian/20/99 (NC). Disease activity was assessed by tender and swollen joint count, morning stiffness, evaluation of pain, Health Assessment Questionnaire, ESR, and C reactive protein on the day of vaccination and six weeks later. Haemagglutination inhibiting (HI) antibodies were tested by a standard WHO procedure. Response was defined as a fourfold or more rise in HI antibodies six weeks after vaccination, or seroconversion in patients with a non-protective baseline level of antibodies (<1/40). Geometric mean titres (GMT) were calculated to assess the immunity of the whole group. Results: Six weeks after vaccination, a significant increase in GMT for each antigen was observed in both groups, this being higher in the healthy group for HK (p = 0.004). The percentage of responders was lower in rheumatoid patients than healthy controls (significant for HK). The percentage of responders was not affected by prednisone or any DMARD, including methotrexate, infliximab, and etanercept. Indices of disease activity remained unchanged. Conclusions: Influenza virus vaccine generated a good humoral response in rheumatoid patients, although lower than in healthy controls. The response was not affected by the use of prednisone or DMARDs.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001C32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:F1BEADA3E98709F72306672C235D47546767CB17 |texte= Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers }}
This area was generated with Dilib version V0.6.33. |